| Primary |
| Malignant Melanoma |
24.6% |
| Drug Use For Unknown Indication |
20.2% |
| Hodgkin's Disease |
19.6% |
| Metastatic Malignant Melanoma |
16.0% |
| Malignant Melanoma Stage Iv |
5.8% |
| Multiple Myeloma |
2.7% |
| Hodgkin's Disease Nodular Sclerosis Stage Unspecified |
1.6% |
| Non-hodgkin's Lymphoma |
1.6% |
| Hypertension |
1.2% |
| Pain |
0.9% |
| Lymphoma |
0.8% |
| Hodgkin's Disease Nodular Sclerosis Stage Ii |
0.6% |
| Hodgkin's Lymphoma |
0.6% |
| Neuroblastoma |
0.6% |
| Prophylactic Chemotherapy |
0.6% |
| Unevaluable Event |
0.6% |
| Hodgkin's Disease Recurrent |
0.5% |
| Hodgkin's Disease Stage Iii |
0.5% |
| Pneumonia |
0.5% |
| Rhabdomyosarcoma |
0.5% |
|
| Pyrexia |
11.9% |
| Thrombocytopenia |
11.3% |
| Pulmonary Embolism |
6.5% |
| Vomiting |
6.5% |
| Metastatic Malignant Melanoma |
6.0% |
| Ureteric Obstruction |
5.4% |
| Pulmonary Toxicity |
4.8% |
| Disease Progression |
4.2% |
| Overdose |
4.2% |
| Pneumonia |
4.2% |
| Staphylococcal Infection |
4.2% |
| Syncope |
4.2% |
| Febrile Neutropenia |
3.6% |
| Hypertension |
3.6% |
| Malignant Melanoma |
3.6% |
| Pleural Effusion |
3.6% |
| Renal Failure |
3.6% |
| Acute Lymphocytic Leukaemia |
3.0% |
| Neutropenia |
3.0% |
| Tumour Lysis Syndrome |
3.0% |
|
| Secondary |
| Hodgkin's Disease |
56.9% |
| Non-hodgkin's Lymphoma |
4.6% |
| Metastatic Malignant Melanoma |
4.5% |
| Malignant Melanoma |
3.8% |
| Lung Neoplasm Malignant |
3.4% |
| Breast Cancer |
3.3% |
| Malignant Melanoma Stage Iv |
3.2% |
| Metastases To Lung |
2.6% |
| Sarcoma |
2.6% |
| Synovial Sarcoma |
2.5% |
| Lymphoma |
2.1% |
| Product Used For Unknown Indication |
1.8% |
| Neuroblastoma |
1.8% |
| Drug Use For Unknown Indication |
1.6% |
| Pain |
1.1% |
| Haematological Malignancy |
1.0% |
| Hodgkin's Disease Recurrent |
0.9% |
| Nausea |
0.8% |
| Hypertension |
0.8% |
| Foetal Exposure During Pregnancy |
0.7% |
|
| Pulmonary Toxicity |
20.5% |
| Febrile Neutropenia |
6.1% |
| Hypothyroidism |
6.1% |
| Toxicity To Various Agents |
6.1% |
| Myelodysplastic Syndrome |
5.8% |
| Thrombocytopenia |
5.1% |
| Pulmonary Embolism |
4.8% |
| Pyrexia |
4.8% |
| Off Label Use |
4.6% |
| Sepsis |
4.6% |
| White Blood Cell Count Decreased |
4.6% |
| Acute Myeloid Leukaemia |
4.3% |
| Pneumonia |
3.5% |
| Death |
3.3% |
| Neutropenia |
2.8% |
| Platelet Count Decreased |
2.8% |
| Vomiting |
2.8% |
| Asthenia |
2.5% |
| Diffuse Large B-cell Lymphoma |
2.5% |
| Pancytopenia |
2.5% |
|
| Concomitant |
| Hodgkin's Disease |
27.8% |
| Chemotherapy |
11.2% |
| Hiv Infection |
6.1% |
| Chronic Lymphocytic Leukaemia |
5.4% |
| Eczema |
5.4% |
| Malignant Melanoma |
5.4% |
| Product Used For Unknown Indication |
4.3% |
| Drug Use For Unknown Indication |
4.2% |
| Lymphoma |
3.9% |
| Pseudolymphoma |
3.9% |
| Metastatic Malignant Melanoma |
3.3% |
| Neutropenia |
3.3% |
| Non-hodgkin's Lymphoma |
3.2% |
| Hodgkin's Disease Stage Iii |
3.0% |
| Angioimmunoblastic T-cell Lymphoma |
2.2% |
| Nausea |
1.7% |
| Prophylaxis |
1.7% |
| Sarcoma |
1.5% |
| Bone Marrow Transplant |
1.2% |
| Vomiting |
1.2% |
|
| Weight Decreased |
8.2% |
| Febrile Neutropenia |
7.3% |
| Pulmonary Toxicity |
7.3% |
| Interstitial Lung Disease |
6.4% |
| Neutropenia |
5.5% |
| Pulmonary Fibrosis |
5.5% |
| Tachycardia |
5.5% |
| Vomiting |
5.5% |
| Wound Infection |
5.5% |
| Rash |
4.5% |
| Scoliosis |
4.5% |
| Vasogenic Cerebral Oedema |
4.5% |
| White Blood Cell Count Decreased |
4.5% |
| Chronic Lymphocytic Leukaemia |
3.6% |
| Disease Progression |
3.6% |
| Dyspnoea |
3.6% |
| Exposure During Pregnancy |
3.6% |
| Neurotoxicity |
3.6% |
| Pneumonitis |
3.6% |
| Pulmonary Haemorrhage |
3.6% |
|
| Interacting |
| Hodgkin's Disease |
30.8% |
| Metastatic Malignant Melanoma |
30.8% |
| Hiv Infection |
23.1% |
| Brain Oedema |
7.7% |
| Convulsion |
7.7% |
|
| Drug Level Decreased |
50.0% |
| Pyrexia |
50.0% |
|
